GENPREX (GNPX) Competitors $0.28 -0.01 (-2.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.12%) As of 07/18/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. INKT, PASG, SCYX, DYAI, ENLV, COEP, TPST, NRSN, CVKD, and CGTXShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors MiNK Therapeutics Passage Bio SCYNEXIS Dyadic International Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics MiNK Therapeutics (NASDAQ:INKT) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk and volatility, INKT or GNPX? MiNK Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, indicating that its stock price is 150% less volatile than the S&P 500. Do analysts recommend INKT or GNPX? MiNK Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 84.64%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe MiNK Therapeutics is more favorable than GENPREX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33GENPREX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, INKT or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-8.06GENPREXN/AN/A-$21.11MN/AN/A Do insiders and institutionals believe in INKT or GNPX? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 14.1% of GENPREX shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 8.5% of GENPREX shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer INKT or GNPX? In the previous week, MiNK Therapeutics had 16 more articles in the media than GENPREX. MarketBeat recorded 16 mentions for MiNK Therapeutics and 0 mentions for GENPREX. MiNK Therapeutics' average media sentiment score of 0.04 beat GENPREX's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Overall Sentiment MiNK Therapeutics Neutral GENPREX Neutral Is INKT or GNPX more profitable? MiNK Therapeutics' return on equity of 0.00% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% GENPREX N/A -664.65%-370.18% SummaryMiNK Therapeutics beats GENPREX on 10 of the 11 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E RatioN/A19.7528.0119.82Price / SalesN/A300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book1.857.678.125.65Net Income-$21.11M-$55.28M$3.25B$257.91M7 Day PerformanceN/A4.85%1.68%3.38%1 Month Performance-8.31%11.70%7.30%11.11%1 Year Performance-85.50%3.69%32.89%18.99% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.3518 of 5 stars$0.28-2.3%N/A-86.2%$9.40MN/A0.0020INKTMiNK Therapeutics2.5408 of 5 stars$7.28+0.6%$37.50+415.5%+111.6%$28.82MN/A-2.8930Analyst DowngradePASGPassage Bio2.5629 of 5 stars$0.43-6.1%$7.50+1,632.1%-68.8%$28.66MN/A-0.42130Stock SplitSCYXSCYNEXIS0.3193 of 5 stars$0.71-3.2%N/A-65.3%$28.54M$3.75M-1.2660DYAIDyadic International3.0274 of 5 stars$0.92-2.6%$6.00+555.4%-29.9%$28.28M$3.49M-4.587Positive NewsGap DownENLVEnlivex Therapeutics1.9018 of 5 stars$1.21+2.5%$10.00+726.4%-13.8%$27.91MN/A-1.8370Positive NewsCOEPCoeptis Therapeutics0.1865 of 5 stars$7.73+2.5%N/A+79.8%$26.49MN/A-1.332TPSTTempest Therapeutics1.5958 of 5 stars$7.08-0.7%$30.00+323.7%-75.1%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.0802 of 5 stars$2.09+9.4%$14.00+569.9%+168.4%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9635 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404Positive NewsCGTXCognition Therapeutics3.1172 of 5 stars$0.58+42.9%$2.83+389.5%-66.3%$25.11MN/A-0.7820High Trading Volume Related Companies and Tools Related Companies INKT Competitors PASG Competitors SCYX Competitors DYAI Competitors ENLV Competitors COEP Competitors TPST Competitors NRSN Competitors CVKD Competitors CGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts